1. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison Clinical and molecular hepatology. 2023;29:252–262; Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Clinical and molecular hepatology. 2023;29:99–101.
2. Wnt signaling in liver regeneration, disease, and cancer;Zou G;Clinical and molecular hepatology,2023
3. Ikeda Met al.. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;Finn RS;The New England journal of medicine,2020
4. Ikeda Met al.. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng AL;Journal of hepatology,2022
5. Korean Liver Cancer A, National Cancer Center K. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma Clinical and molecular hepatology. 2022;28:583–705; Goh MJ, Sinn DH, Kim JMet al.. Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective Clinical and molecular hepatology. 2023;29:197–205.